Canada: March 2017 Deal Round-Up

Last Updated: April 13 2017
Article by Cameron Mingay

The following is a selection of major deals in the life science space that closed or were announced as closed in March 2017.

Date: March 3, 2017

Type: Acquisition

Target: Valeant Pharmaceuticals International, Inc. ("Valeant") (NYSE: VRX; TSX:VRX) (specifically, Valeant's CeraVe, AcneFree and AMBI skincare brands)

Acquirer: L'Oréal SA ("L'Oréal")

Deal size: US $1.3 billion

Description: On March 3, 2017, Valeant announced the completion of the sale of its CeraVe, AcneFree and AMBI skincare brands to L'Oréal SA for cash consideration of $1.3 billion. Valeant indicated that the rationale for the sale was to generate cash to pay down debt while L'Oréal indicated that it purchased these brands in order to, among other things, complement L'Oréal's current brand portfolio.

*On March 21, 2017, Valeant also completed a number of major refinancing transactions. See "Valeant Completes Refinancing Transactions" for more information.

Source: Valeant Pharmaceuticals Inc. (March 3, 2017), "Valeant Pharmaceuticals Completes Sale of CeraVe, AcneFree and AMBI Skincare Brands to L'Oréal".
Date: March 9, 2017

Type: Bought deal public offering

Issuer: Cronos Group Inc. ("Cronos Group") (TSXV: MJN)

Underwriter(s): A syndicate of underwriters led by Eight Capital and which included PI Financial Corp., Beacon Securities Limited, GMP Securities L.P., Cormark Securities Inc. and Mackie Research Capital Corp.

Deal size: Aggregate gross proceeds of approximately CDN $17.3 million

Description: On March 9, 2017, Cronos Group announced the closing of a bought deal public offering, including the full exercise of the over-allotment option (the "Offering") for aggregate gross proceeds of approximately CDN $17.3 million. A total of 7,705,000 common shares of Cronos Group were sold at a price of $2.25 per share. Cronos Group intends to use the net proceeds to, among other things, expand production capacity at its wholly-owned companies Peace Naturals Project Inc. and In The Zone Produce Ltd.

Source: Cronos Group Inc. (March 9, 2017), "Cronos Group Announces Closing of Previously Announces $17 Million Bought Deal"
Date: Announced March 14, 2017

Type: Series C financing

Issuer: CellAegis Devices Inc. ("CellAegis")

Investor(s): Financing led by CTI Life Sciences Fund, and co-led by a U.S. based strategic investor, with other investors including MaRS Catalyst Fund, Broadview Ventures, and strategic family offices.

Deal size: US $9.5 million

Description: On March 14, 2017, CellAegis announced the closing of a US $9.5 million Series C financing to support a U.S. clinical trial and de novo 510(k) regulatory filing for marketing of its autoRIC Device as an adjunct therapy to stenting.

Source: CellAegis Devices Inc. (March 14, 2017), "CellAegis Devices Announced US $9.5 Million Financing to Support Clinical and Regulatory advancement of its autoRIC Device".
Date: March 16, 2017

Type: Public offering

Issuer: Titan Medical Inc. ("Titan") (TSX: TMD)

Agent: Bloom Burton Securities Inc.

Deal size: Gross proceeds of CDN $7,513,520

Description: On March 16, 2017, Titan announced the closing of its public offering (the "Offering") of 21,467,000 units (each a "Unit") at a price of CDN $0.35 per Unit for gross proceeds of CDN $7,513,520. Each Unit was comprised of one common share of Titan (a "Common Share") and (i) one-half of one Common Share purchase warrant, each whole warrant exercisable for one Common Share, at a price of CDN $0.40 for a period of two years following the closing of the Offering (the "Closing"), and (ii) one-half of one Common Share purchase warrant, each whole warrant exercisable for one Common Share, at a price of CDN $0.50 for a period of four years following Closing. Titan is a Canadian company focused on the development and commercialization of computer-assisted robotic surgical technologies for application in minimally invasive surgery.

Source: Titan Medical Inc. (March 16, 2017), "Titan Medical Inc. Announces closing of Public Offering".
Date: March 20, 2017

Type: Public offering

Issuer: Aurinia Pharmaceuticals Inc. ("Aurinia") (NASDAQ: AUPH) (TSX: AUP)

Underwriter(s): Leerink Partners LLC and Cantor Fitzgerald & Co. (the "Underwriters") acted as joint book-running managers for the public offering.

Deal size: Approximately US $173.1 million

Description: On March 20, 2017, Aurinia announced the closing of its public offering (the "Offering") of 25,645,000 common shares, including 3,345,000 common shares pursuant to the full exercise of the underwriters' option to purchase additional common shares. The shares were sold at a price of US $6.75 per share for gross proceeds of approximately US $173.1 million. Aurinia is a clinical stage biopharmaceutical company currently developing an investigational drug for the treatment of lupus nephritis. The company intends to use the net proceeds of the Offering to advance Phase 3 clinical trial activities for lupus nephritis and for working capital purposes.

Source: Aurinia Pharmaceuticals Inc. (March 20, 2017), "Aurinia Closes US $173.1 Million Public Offering of Common Shares and Full Exercise of Underwriters' Option to Purchase Additional Common Shares.
Date: March 22, 2017

Type: Seed stage financing

Issuer: Propellon Therapeutics Inc. ("Propellon")

Deal size: CDN $3.0 million

Investor(s): Fight Against Cancer Innovation Trust ("FACIT"), along with the contribution of certain non-dilutive capital to achieve the $3.0 million financing.

Description: On March 22, 2017, FACIT announced a seed stage investment in Propellon, a start-up created by FACIT to develop a portfolio of WDR5-targeted anti-cancer therapeutics. The funding will be used to speed up the nomination of a candidate drug, set up the company for further financing rounds, and/or enter a partnership for clinical trials in patients with haematological cancers.

Source: FACIT (March 22, 2017), "FACIT Announces Investment in Propellon Therapeutics"
Date: March 22, 2017

Type: Private Placement

Issuer: Canopy Growth Corporation ("Canopy") (TSX: WEED)

Investor: One undisclosed investor

Deal size: Aggregate net proceeds of $24,250,000

Description: On March 22, 2017, Canopy announced that it had completed a private placement (the "Offering") of 2,500,000 common shares at a net price of $9.70 per share to one investor, for aggregate net proceeds of $24,250,000. The company intends to use the proceeds of the Offering for, among other things, capacity growth initiatives.

Source: Canopy Growth Corporation (March 22, 2017), "Canopy Growth Completes $24.25 Million Private Placement Financing.
Date: March 28, 2017

Type: Series A financing

Issuer: Resolve Digital Health Inc. ("Resolve")

Broker: Canaccord Genuity Group Inc.

Investor(s): Financing led by Aphria Inc.

Deal size: $5 million

Description: On March 28, 2017, Resolve completed a $5 million Series A financing led by Aphria Inc. and brokered by Canaccord Genuity Group Inc. Resolve is a provider of standardized medical cannabis for patients suffering from cancer, arthritis, migraine headaches, chronic pain and other diseases.

Source: Resolve Digital Health (March 28, 2017), "Resolve Digital Health Raises $5 million to Debut the First Standardized Patient Experience for Medical Cannabis".

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.